These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 13255811

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Experience in the treatment of hypertension with pentapyrrolidinium (ansolysen) in a hypertension outpatient clinic.
    POMERANTZ HZ, BARSKY S, GORDON L, WENER J.
    Can Med Assoc J; 1957 Aug 15; 77(4):325-8. PubMed ID: 13446819
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Blood pressure reduction in arterial hypertension by hexamethonium and pentapyrrolidinium salts.
    SMIRK FH.
    Am J Med; 1954 Dec 15; 17(6):839-50. PubMed ID: 13207165
    [No Abstract] [Full Text] [Related]

  • 31. Hexamethonium-its effect on glomerular filtration rate, maximal tubular function and renal excretion of electrolytes.
    MOYER JH, MILLS LC.
    J Clin Invest; 1953 Feb 15; 32(2):172-84. PubMed ID: 13022775
    [No Abstract] [Full Text] [Related]

  • 32. Pentapyrrolidinium bitartrate (M. & B. 2050A) in the treatment of hypertension; preliminary observations.
    GIFFORD RW, ALLEN EV, BIRKHEAD NC.
    Proc Staff Meet Mayo Clin; 1954 Sep 01; 29(18):496-508. PubMed ID: 13204389
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The drug treatment of severe hypertensive disease, with particular reference to hydralazine and pentapyrrolidinium.
    HOOBLER SW.
    Trans Am Coll Cardiol; 1955 Dec 01; 5():101-6. PubMed ID: 13274398
    [No Abstract] [Full Text] [Related]

  • 36. Treatment of hypertension with reserpine, with reserpine in combination with pentapyrrolidinium, and with reserpine in combination with Veratrum alkaloids.
    DOYLE AE, McQUEEN EG, SMIRK FH.
    Circulation; 1955 Feb 01; 11(2):170-81. PubMed ID: 13231254
    [No Abstract] [Full Text] [Related]

  • 37. Heart-failure from retention of salt and water caused by treatment with pentapyrrolidinium bitartrate.
    RØNNOV-JESSEN V.
    Lancet; 1955 Jan 15; 268(6855):122-4. PubMed ID: 13222863
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [Experiments and considerations on a synthetic curare-like agent. I. Effects of the functional exclusion of the liver and kidney on the muscle-relaxant action in the rabbit].
    CACCIAVILLANI E.
    Arch Sci Med (Torino); 1961 Nov 15; 112():361-70. PubMed ID: 13875438
    [No Abstract] [Full Text] [Related]

  • 40. Renal response to pentolinium: laboratory observations.
    MOYER JH, HANDLEY CA, HALL A, MAZEIKA M.
    Am J Med Sci; 1956 Feb 15; 231(2):134-9. PubMed ID: 13282894
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.